Drugs in MeSH Category Platelet Aggregation Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996		DISCN	Yes	No
Mylan Institutional	MILRINONE LACTATE	milrinone lactate	INJECTABLE;INJECTION	076428-001	Jun 16, 2003		DISCN	No	No
Sanofi Aventis Us	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	milrinone lactate	INJECTABLE;INJECTION	020343-001	Aug 9, 1994		DISCN	Yes	No
Ani Pharms	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	086944-002	Apr 16, 1991		DISCN	No	No
Hec Pharm	PRASUGREL	prasugrel hydrochloride	TABLET;ORAL	206021-002	Jan 16, 2019	AB	RX	No	No
Sanofi Aventis Us	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	milrinone lactate	INJECTABLE;INJECTION	020343-003	Aug 9, 1994		DISCN	Yes	No

Platelet Aggregation Inhibitors: Market Dynamics and Patent Landscape in NLM MeSH Class

Last updated: April 26, 2026

What defines the NLM MeSH scope for “Platelet Aggregation Inhibitors”?

NLM MeSH uses the concept “Platelet Aggregation Inhibitors” to group drugs that reduce platelet aggregation. In market and patent work, this MeSH class typically maps to antiplatelet therapeutics used for thrombotic disease prevention, dominated by P2Y12 inhibitors, COX-1 (aspirin) inhibition, and GP IIb/IIIa antagonists. The MeSH class is not limited to one mechanism, but mechanism breadth matters for patentability because each target family has distinct patent timing, formulation strategies, and life-cycle patterns (new salts, dosing regimens, extended-release, combination products). MeSH also supports cross-indexing with specific platelet receptor targets, cyclooxygenase pathways, and thrombotic indications.

Core therapeutic mechanism buckets relevant to the MeSH class

• COX-1 inhibition: aspirin (acetylsalicylic acid) and related salicylates where used as antiplatelet therapy
• P2Y12 inhibition: clopidogrel, prasugrel, ticagrelor; newer agents in the pipeline are typically also P2Y12-directed
• GP IIb/IIIa inhibition: abciximab, eptifibatide, tirofiban
• Other platelet aggregation pathways: includes agents with different receptor or intracellular targets where the clinical purpose is antiplatelet activity

How do market dynamics shape R&D priorities in antiplatelet therapy?

Platelet aggregation inhibitors sit in a mature chronic and recurrent-care market driven by cardiovascular and cerebrovascular events. Market dynamics shift R&D emphasis toward: (1) improved safety profiles, (2) easier dosing, and (3) sharper benefit in high-risk or specific biomarker-defined subpopulations. The competitive set is anchored by guideline-based use in acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), secondary prevention after myocardial infarction and stroke, and off-label use patterns.

Demand drivers

• Secondary prevention remains the core volume engine: recurrent-risk populations sustain long-duration use, especially for P2Y12 inhibitors and aspirin-based regimens.
• ACS and PCI are high-value cycles: rapid uptake and strong formulary leverage for DAPT and peri-procedural antiplatelet strategies.
• Bleeding risk is the gating endpoint: net clinical benefit increasingly depends on bleeding reduction and reversibility rather than pure antithrombotic intensity.

Pricing and access dynamics

• Biosimilar dynamics are mostly irrelevant for small-molecule P2Y12 inhibitors, but access pressure grows via generics for older agents.
• Formulary scrutiny targets net benefit and dose practicality: once-daily regimens, predictable pharmacokinetics, and fewer drug-drug interactions have economic impact.
• Regional reimbursement differs by bleeding risk tolerance: markets with stricter bleeding constraints favor agents with measurable safety advantages in head-to-head trials.

Competitive dynamics

• Generic erosion is the baseline for older P2Y12 agents: clopidogrel is widely generic; prasugrel is also fully generic in many geographies; aspirin is long-expired in most markets.
• Differentiation clusters around safety and dosing: ticagrelor remains a benchmark; new entrants must demonstrate meaningful advantage in bleeding, tolerability, or outcomes in defined subgroups.
• Combination and regimen innovation is a dominant life-cycle lever: fixed-dose combinations with aspirin or co-formulation to reduce dosing friction frequently appears in late-stage patenting.

What is the patent landscape structure for platelet aggregation inhibitors?

The patent landscape for this MeSH class typically shows a two-layer structure:

1. API-origin patents: target receptor chemistry, compounds, and first clinical use claims. These set the core exclusivity timeline.
2. Life-cycle and regulatory-expansion patents: new salt forms, crystal forms, polymorphs, prodrugs, formulation advances, dosing regimens, fixed-dose combinations, and new indications. These often extend exclusivity for brand incumbents and block narrow generic entry paths.

Typical life-cycle patent playbooks in antiplatelet therapy

• Formulation and delivery
  • improved tablet formulations, modified-release, improved bioavailability
• Salt/crystal polymorph expansion
  • new solid forms that survive obviousness rejections
• Dosing regimen claims
  • loading-dose/maintenance-dose timing, reduced dose strategies for safety
• Combination products
  • fixed-dose combinations with aspirin or co-therapy regimens
• New patient populations
  • biomarker-stratified subgroups, renal impairment cohorts, elderly bleeding-risk cohorts

Where are the main patent pressure points (and why do they matter commercially)?

Because the MeSH class is dominated by mature drugs, the commercial battleground often shifts to:

• Narrow method-of-use claims that still block certain labeling-driven generic substitution
• Regimen- or population-specific claims that prevent “easy” generic launches in specific settings
• Formulation patents that complicate ANDA-style entry via process and solid-form differences

For investors and R&D planners, the key is that generic entry is rarely blocked by broad mechanism claims; it is blocked by enforceable, specific claims tied to product identity (form, dose, regimen) or labeling.

What does the patent landscape look like by major mechanism family?

The MeSH class includes multiple pharmacologic families. Patent density and remaining enforceability differ by family due to older origin dates and stronger generic penetration for earlier entrants.

P2Y12 inhibitors

• Clopidogrel: early origin era with widespread generic penetration. Patent activity is largely focused on:
  • line extensions outside core use
  • regimen claims where still relevant (primarily in specific jurisdictions or labeling frameworks)
• Prasugrel: similar mature profile with heavy genericization; late patents often focus on regimen and population refinements.
• Ticagrelor: comparatively newer and still supported by remaining life-cycle claims in some jurisdictions depending on filing and continuation strategy. Patent activity tends to focus on:
  • dosing and regimen refinements
  • combinations and subpopulation benefit claims

Commercial effect: P2Y12 is where most market share has concentrated historically, so most new entrants focus on differentiating safety and reversibility (or superior outcomes in bleeding-prone cohorts). Patent enforcement also becomes more targeted, often centered on specific label uses.

COX-1 inhibition (aspirin-based therapy)

Aspirin’s patent footprint is largely historical and does not drive contemporary exclusivity in most major markets. Most patent activity appears in:

• specific formulations (especially where dosing convenience or combination changes create patentable compositions)
• combination regimens and novel delivery approaches (where clinically used)

Commercial effect: aspirin rarely creates a new patent moats; it more often becomes part of combination and regimen patents around other antiplatelet agents.

GP IIb/IIIa inhibitors

These agents have smaller market share and tend to be used in acute procedural settings. Patent activity has typically narrowed to:

• use methods
• dosing regimen variations
• formulation changes to support administration in acute care settings

Commercial effect: GP IIb/IIIa is less likely to generate large new entrants due to mature competition and limited room for differentiation, but procedural-specific patents can still matter for exclusive distribution channels.

How do new-drug and life-cycle strategies compete against expiring exclusivity?

Patent strategy in platelet aggregation inhibition increasingly follows a “stack”:

• Early composition-of-matter (MoA) coverage for the active compound
• Continuation filings to expand claim scope to particular salts, polymorphs, and specific formulations
• Method-of-use claims for clinical subgroups, dosing schedules, and combination regimens
• Regulatory and label leverage: patent enforceability is strongest when claims align with labeled indications and dosing instructions

In the market, this translates into:

• Brand incumbents extending exclusivity through regimen and formulation patenting tied to clinical practice guidelines
• Generic entrants targeting “design-around” strategies in:
  • solid form selection
  • release profile differences
  • regimen mismatch with the strictest method-of-use claims

What role do regulatory and patent linkage systems play?

Patent linkage frameworks (jurisdiction-dependent) can slow generic entry when a brand lists patents covering the drug. For antiplatelet drugs, where method-of-use and formulation patents can be listed, linkage can become a practical barrier for delayed launch.

From an investment lens, the linkage status and patent listing completeness often matter as much as the underlying patent strength because they can control entry timelines.

Key market segments driving patent value

Patent value concentrates where:

• there is high event rate (ACS/PCI, secondary prevention)
• DAPT or long-duration therapy is routine
• bleeding risk differentiation can shift prescribing behavior
• there is a strong evidence base that supports label claims

Segment mapping to mechanism families

• ACS and PCI: dominated by P2Y12 inhibitors and peri-procedural agents (including GP IIb/IIIa in specific cases)
• Chronic secondary prevention: typically aspirin plus a P2Y12 inhibitor in appropriate risk windows, or aspirin monotherapy when combination is unsuitable
• High bleeding-risk cohorts: drives life-cycle claims around dose reduction, reduced-intensity regimens, or selection of agents with favorable bleeding profiles

Patent watchlist priorities for R&D and licensing

For a MeSH class spanning platelet aggregation inhibition broadly, the actionable patent watchlist focuses on three claim types that most often survive enforcement in this therapeutic area.

1) Solid-state and formulation claims

• new salts
• polymorphs/crystal forms
• excipient systems that support release and bioavailability
• manufacture process claims that are tied to specific product identity

2) Method-of-use and dosing regimen claims

• loading-dose/maintenance-dose instructions
• timing around PCI or acute events
• dose reduction protocols for specific risk groups (often elderly or renal impairment)

3) Combination product claims

• fixed-dose combinations with aspirin
• co-administration regimen claims intended to fit clinical pathways

What does this mean for near-term market entry timing?

In practice:

• Generic entry risk is highest when only broad mechanism coverage remains and when label protections lapse.
• Commercially meaningful “delay” patterns emerge when patents remain on:
  • formulations that must be used for bioequivalence pathways
  • regimen-specific methods that are hard to “genericize” without claim design-around
  • combination products that lock in co-prescription patterns

Key Takeaways

• The NLM MeSH class “Platelet Aggregation Inhibitors” maps to a mature antithrombotic market dominated by P2Y12 inhibitors, aspirin-based therapy, and GP IIb/IIIa antagonists.
• Market dynamics prioritize bleeding-risk improvement, dosing convenience, and regimen precision, which in turn drive patent strategies around dosing, formulations, and combinations.
• The patent landscape is structured as origin-compound coverage plus stacked life-cycle filings, with enforceable value concentrated in solid-state/formulation claims and method-of-use regimen claims that align with labeled clinical practice.
• For entry timing, generic risk is highest for expiring broad API coverage; delays cluster around specific, product-identity-linked patents and linkage-driven patent listings.

FAQs

1. Which antiplatelet drug families most often drive MeSH “Platelet Aggregation Inhibitors” market share?
   P2Y12 inhibitors and aspirin-based regimens account for the majority of chronic and ACS/PCI demand; GP IIb/IIIa antagonists are procedural and more limited.

2. What patent claim types most reliably affect generic launch timing in this class?
   Solid-state and formulation patents, method-of-use/dosing regimen patents, and combination-product patents tied to labeled instructions.

3. Why do dosing and regimen patents matter more than broad mechanism patents for generics?
   Because generics can often rely on API equivalence while design-around attempts focus on product and labeled dosing specificity where method claims are enforceable.

4. Where do new entrants typically target differentiation?
   Bleeding safety, dosing practicality, and subgroup-specific outcome advantages that can support label expansion and durable method-of-use claims.

5. How does regulatory patent linkage influence the economics of entry?
   It can delay generic launches when listed patents cover brand-relevant formulations and method-of-use claims that align with labeling.

---

References

[1] National Library of Medicine. MeSH: Platelet Aggregation Inhibitors. https://meshb.nlm.nih.gov/ (MeSH concept page for “Platelet Aggregation Inhibitors”).
[2] U.S. Food and Drug Administration. Drugs@FDA: Drug product information and labeling access (for antiplatelet drug labels and indication/dosing sections). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] European Medicines Agency. EPAR documents and product information (for antiplatelet indication and dosing references). https://www.ema.europa.eu/en/medicines